AKT1 and B-cell chronic lymphocytic leukemia: These results indicate that PI3K/AKT pathway activation in CLL (by myrAKT1 overexpression, genetic SHIP1 deletion, or by SHIP1 inhibition) promotes the oxidative metabolic pathway in CLL and thereby leads to the formation of toxic ROS levels.